Meissa Vaccines Begins Study of RSV Vaccine Candidate in Seronegative Children
Excerpt from the Press Release:
REDWOOD CITY, Calif.–(BUSINESS WIRE)–Meissa Vaccines (“Meissa”), a biotechnology company developing vaccines to prevent serious viral respiratory infections, announced today the first seronegative participants have received MV-012-968, Meissa’s intranasal live attenuated RSV vaccine candidate, in a Phase 1c study in infants and young children. The study is enrolling up to 45 participants between the ages of six and 24 months at three sites in the U.S. to evaluate the safety and immunogenicity of MV-012-968 (ClinicalTrials.gov Identifier: NCT04909021). Meissa is developing MV-012-968 as a needle-free, adjuvant-free vaccine to protect infants and at-risk, older adults from respiratory syncytial virus (RSV).
RSV is a leading cause of respiratory infections such as bronchiolitis and viral pneumonia in infants. In the United States, approximately 1% of infants are hospitalized because of RSV each year. Globally in children under 5 years of age, RSV causes more than 66,000 deaths per year and approximately three million hospitalizations (Anderson 2013). Since the discovery of RSV in 1956, no vaccine has been approved for prevention.
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?